Bronsveld Heleen K, Jensen Vibeke, Vahl Pernille, De Bruin Marie L, Cornelissen Sten, Sanders Joyce, Auvinen Anssi, Haukka Jari, Andersen Morten, Vestergaard Peter, Schmidt Marjanka K
Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
PLoS One. 2017 Jan 11;12(1):e0170084. doi: 10.1371/journal.pone.0170084. eCollection 2017.
Women with diabetes have a worse survival after breast cancer diagnosis compared to women without diabetes. This may be due to a different etiological profile, leading to the development of more aggressive breast cancer subtypes. Our aim was to investigate whether insulin and non-insulin treated women with diabetes develop specific clinicopathological breast cancer subtypes compared to women without diabetes.
This cross-sectional study included randomly selected patients with invasive breast cancer diagnosed in 2000-2010. Stratified by age at breast cancer diagnosis (≤50 and >50 years), women with diabetes were 2:1 frequency-matched on year of birth and age at breast cancer diagnosis (both in 10-year categories) to women without diabetes, to select ~300 patients with tumor tissue available. Tumor MicroArrays were stained by immunohistochemistry for estrogen and progesterone receptor (ER, PR), HER2, Ki67, CK5/6, CK14, and p63. A pathologist scored all stains and revised morphology and grade. Associations between diabetes/insulin treatment and clinicopathological subtypes were analyzed using multivariable logistic regression. Morphology and grade were not significantly different between women with diabetes (n = 211) and women without diabetes (n = 101), irrespective of menopausal status. Premenopausal women with diabetes tended to have more often PR-negative (OR = 2.44(95%CI:1.07-5.55)), HER2-negative (OR = 2.84(95%CI:1.11-7.22)), and basal-like (OR = 3.14(95%CI:1.03-9.60) tumors than the women without diabetes, with non-significantly increased frequencies of ER-negative (OR = 2.48(95%CI:0.95-6.45)) and triple negative (OR = 2.60(95%CI:0.88-7.67) tumors. After adjustment for age and BMI, the associations remained similar in size but less significant. We observed no evidence for associations of clinicopathological subtypes with diabetes in postmenopausal women, or with insulin treatment in general.
We found no compelling evidence that women with diabetes, treated with or without insulin, develop different breast cancer subtypes than women without diabetes. However, premenopausal women with diabetes tended to develop breast tumors that do not express hormonal receptors, which are typically associated with poor prognosis.
与非糖尿病女性相比,糖尿病女性在乳腺癌诊断后的生存率更低。这可能是由于病因不同,导致更具侵袭性的乳腺癌亚型的发展。我们的目的是研究与非糖尿病女性相比,接受胰岛素治疗和未接受胰岛素治疗的糖尿病女性是否会发展出特定的临床病理乳腺癌亚型。
这项横断面研究纳入了2000年至2010年期间随机选取的浸润性乳腺癌患者。根据乳腺癌诊断时的年龄(≤50岁和>50岁)进行分层,糖尿病女性与非糖尿病女性按出生年份和乳腺癌诊断时的年龄(均按10年分组)以2:1的频率匹配,以选取约300例有肿瘤组织的患者。肿瘤微阵列通过免疫组织化学法检测雌激素和孕激素受体(ER、PR)、HER2、Ki67、CK5/6、CK14和p63。一名病理学家对所有染色进行评分,并修订形态学和分级。使用多变量逻辑回归分析糖尿病/胰岛素治疗与临床病理亚型之间的关联。无论绝经状态如何,糖尿病女性(n = 211)和非糖尿病女性(n = 101)之间的形态学和分级没有显著差异。绝经前糖尿病女性比非糖尿病女性更常出现PR阴性(OR = 2.44(95%CI:1.07 - 5.55))、HER2阴性(OR = 2.84(95%CI:1.11 - 7.22))和基底样(OR = 3.14(95%CI:1.03 - 9.60))肿瘤,ER阴性(OR = 2.48(95%CI:0.95 - 6.45))和三阴性(OR = 2.60(95%CI:0.88 - 7.67))肿瘤的频率也有非显著增加。在调整年龄和BMI后,关联的大小相似但显著性降低。我们没有观察到绝经后女性临床病理亚型与糖尿病之间或总体上与胰岛素治疗之间存在关联的证据。
我们没有找到令人信服的证据表明,接受或未接受胰岛素治疗的糖尿病女性与非糖尿病女性发展出不同的乳腺癌亚型。然而,绝经前糖尿病女性倾向于发展出不表达激素受体的乳腺肿瘤,这些肿瘤通常与预后不良相关。